Welcome to our dedicated page for Optimi Health news (Ticker: OPTH), a resource for investors and traders seeking the latest updates and insights on Optimi Health stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Optimi Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Optimi Health's position in the market.
Optimi Health (NASDAQ: OPTH) has produced two naturally derived microdose psilocybin finished drug products at 1 mg and 2 mg, available to authorized clinical research organizations. The capsules offer validated, consistent dosing and extend Optimi's psilocybin range, which includes a 5 mg capsule prescribed for treatment-resistant depression in Australia.
All products are manufactured end-to-end at Optimi's GMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment License, for export to regulated international markets.
Optimi Health (NASDAQ: OPTH) completed its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial.
The shipment includes psilocybin biomass and 5mg capsules made at Optimi’s Canadian GMP facility under Health Canada and UK Home Office authorizations.
Optimi Health (NASDAQ: OPTH) announced progress on its Ibogaine Initiative, securing naturally derived ibogaine from two sources in hydrochloride and freebase forms. Finished drug product development is expected to begin this summer at its GMP facility in British Columbia.
Optimi plans encapsulated 50mg and 100mg ibogaine doses, developing SOPs for encapsulation, bottling, labeling, packaging, and validating manufacturing and analytical methods. A recent U.S. executive order prioritizing ibogaine for accelerated FDA review, along with Canada’s regulatory framework and Optimi’s Health Canada licensing, is described as positioning Canada and Optimi as an advantageous base for compliant ibogaine supply.
Optimi Health (NASDAQ: OPTH) completed a GMP production run of its 5mg psilocybin capsules, already prescribed in Australia for treatment-resistant depression. The run also supplies upcoming clinical research in the United States and clinical trials in Europe, with improved bottling for the Australian market.
All stages, from biomass cultivation to packaging, were completed in-house under a Health Canada Drug Establishment Licence, supporting vertically integrated, commercial-scale supply with secure storage capacity and international distribution of psilocybin and MDMA drug products.
Optimi Health (NASDAQ: OPTH) highlighted updated Therapeutic Goods Administration recommendations for Australia's Authorized Prescriber framework covering prescribed psilocybin and MDMA.
The changes broaden therapist eligibility, permit treatment in more medically supervised settings, confirm no serious adverse events since December 2025, and extend reimbursement across public and private payers.
Optimi Health (NASDAQ: OPTH), a commercial-stage manufacturer of regulated psychedelic drug products, completed a production run of a naturally derived psilocybin extract measuring about 6% psilocybin, its highest-purity botanical extract to date.
The extract will support Australian treatment-resistant depression prescriptions, upcoming European clinical research, and ongoing product development, while aggregate Scheme data to December 2025 report no serious adverse events.
Optimi Health (NASDAQ: OPTH) closed an oversubscribed underwritten public offering of 2,400,000 common shares at US$6.25 per share, raising US$15 million in gross proceeds in connection with its uplisting to the Nasdaq Capital Market.
The shares began trading on Nasdaq on May 20, 2026 under OPTH and continue on the CSE as OPTI. The underwriter received 96,000 warrants exercisable at US$7.50 per share until May 21, 2031.
Optimi Health (Nasdaq: OPTH) priced an oversubscribed underwritten public offering of 2,400,000 common shares at US$6.25 per share, for expected gross proceeds of about US$15 million, alongside an uplisting to the Nasdaq Capital Market effective May 20, 2026.
The company also completed a 1‑for‑30 share consolidation on May 19, 2026, leaving approximately 3,225,881 shares outstanding before the offering and any underwriter option exercises.